Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Green box that must be Jimbo.. haha
Great RNS this morning, can see a significant lift shortly lol
Well done to all who held there nerve.
Just to be clear, the news is great. Massive production capacity and huge potential. If I’m wrong and this flies then happy days. I’m just tempering my own expectation and not expecting to break the 150 resistance with no validation and completed trials
Huh? lol.....IMO not the info I wanted to see this morning, even the can is getting worn away now!
Another NCYT twat pretending he’s in, sorry mate this RNS is a significant one
Awesome news, very pleased with that one. Gonna make this coffee Irish to celebrate.
jimmy have a day off.... You’re boring af.
Doggy 100 why gave you reported Jimboo ? Because he didn't agree with you ?
Chengdo your a good poster
Don’t wAist your intelligence
Filter him and report
Agreed jimboo. Of course you want get any fans posting it but it will spike to over 150 then by this time next week will be back to 130s.
And filterered
The rest do the same it’s quick and easy like our test!!!
It’s a very decent RNS indeed tbh, and other global partners in the pipeline to meet demand globally...i think this RNS should settle some of the nerves for the people that were sitting on the edge and getting nervous about their investment.
Agree we’ll hopefully see an uptick to/past 150p, and also hopefully a stop to the tide going out every week down to 120s then back up so we can consolidate a solid platform from which to launch the AVCT rocket when we receive the blast off RNS on validation and manufacture maybe 6-8 weeks time. And not forgetting the real beneficiaries here, hopefully all in time to help you, me and the world to better control what seems to be an inevitable second, maybe greater than the first, peak in winter. GLA
That’s made my holiday bit better.
Patience is key but looks like the team have been getting everything ready for large scale execution.
Millions of tests sounds awesome and maybe FDA to follow would be cherry on cake
Credit where credit is due I have always though avacta was jam but well done on that holders. All the best
I disagree. I think the SP will move significantly on this for two reasons:
1. Confidence / FOMO: This RNS will reassure the doubters and shows that big news is coming soon.
2. Scale: Tall of “millions” of tests per month, combined with the confidence of a manufacturing partner being in place.
Maybe not THE big jump up, but it will have an effect. We’ll see very shortly, and I’m not selling anyway. :)
DM83 ...it was posted on BB that Sona had a similar announcement when their LFT was ready from Cytiva. Did not stop the Sona share price motoring x4 in a short period of time.
Govts can now prepare the contracts as we are ready .. Excellent.
Test, test, test
Making a product that the tw@s were trying to spread rumours of failure :)
Nice update and I’m glad we’ve gone from ‘Shortly’ to ‘As soon as possible’
DM83
I doubt it will have a adverse effect though.!!
Great news but I doubt it will do much to the share price today. No sales data, and no date for production. Just more time needed for data transfer.
Don’t get me wrong, long term this is great news with the ramping up of capacity to a huge number and now worldwide, but I don’t think the SP will make moves today.
Thanks
Glad i haven't sold any yet.
Avacta Group PLC COVID-19 Rapid Antigen Test Manufacturing Partner
Source: UK Regulatory (RNS & others)
TIDMAVCT
RNS Number : 2934V
Avacta Group PLC
06 August 2020
06 August 2020
Avacta Group plc
("Avacta" or "the Group" or "the Company")
COVID-19 Rapid Antigen Test Manufacturing Partner
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that it has appointed BBI Solutions, part of BBI Group ("BBI"), to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva.
BBI Solutions is a leading global developer and manufacturer of raw materials and finished test products for the in-vitro diagnostics market, with manufacturing sites in five different countries, spanning four continents .
The manufacturing agreement between Avacta and BBI comprises the accelerated development and validation of a scaled-up manufacturing process that has the potential to ramp up to a production capacity of millions of tests per month. Avacta, Cytiva and BBI are in the process of the technology transfer of the prototype and related manufacturing procedures for the saliva-based rapid
SARS-CoV-2 antigen test from Cytiva to BBI.
Avacta aims to begin clinical validation of the test as soon as possible by using the first pilot batches generated as part of the technology transfer process for these studies. In parallel with these clinical validation studies, which will be run within the UK government's CONDOR programme and potentially with other collaborators globally, BBI will work with Avacta and Cytiva to produce the additional technical documentation that is required for CE marking of the final product.
Dr. Alastair Smith, Chief Executive of Avacta Group commented:
"I am delighted to be working with BBI to manufacture the rapid COVID-19 test. BBI has been excellent to work with to define a highly compressed product development timeline that will allow us to get the product to market as quickly as possible.
We anticipate very high demand for the COVID-19 rapid test and will be working with our preferred manufacturing partners at BBI to satisfy that demand. We are actively continuing our discussions with other manufacturing partners to ensure that we have access to additional manufacturing capacity to address the global need for SARS-CoV-2 antigen testing both now, and in the next few years.
As we set out in the use of proceeds at the recent fund raising, we have now expanded our product development team with the appointment of an experienced in-vitro diagnostic Product Development Manager, and we are expanding the protein production facilities in order to meet the expected demand for Affimer proteins for the COVID-19 tests and future diagnostic tests in the pipeline.
The diagnostics business has also been